Erlonix 100 mg (Tablet)
Unit Price: ৳ 600.00 (3 x 10: ৳ 18,000.00)
Strip Price: ৳ 6,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- First-line treatment of metastatic Non-Small Cell Lung cancer (NSCLC) with specific mutations
- Maintenance treatment of locally advanced or metastatic NSCLC
- Treatment of locally advanced or metastatic NSCLC after failure of prior chemotherapy regimen
- First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine
Description
Erlonix is a kinase inhibitor with chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Reversibly inhibits EGFR kinase activity and prevents downstream signaling.
Dosage & Administration
- Recommended daily dose for NSCLC is 150 mg on empty stomach
- Recommended daily dose for pancreatic cancer is 100 mg in combination with gemcitabine
CYP3A4 Inhibitors
- Interaction with potent inhibitors like ketoconazole and Ciprofloxacin
CYP3A4 Inducers
- Pre-treatment with rifampicin decreased Erlonix exposure
- Increase doses by 50 mg increments with CYP3A4 inducers like rifampin at 2 week intervals
Concurrent Cigarette Smoking
Requires dose adjustment with increments and reduction upon cessation
Anticoagulants Interaction
Can lead to increased International Normalized Ratio (INR)
Side Effects
- Common adverse reactions include rash, diarrhea, anorexia, and more
- Serious adverse reactions include Interstitial Lung Disease (ILD), Renal Failure, Hepatotoxicity, Gastrointestinal Perforation, Myocardial Infarction/Ischemia, and more
Pregnancy & Lactation
- Pregnancy category D
- Potential fetal harm when administered to pregnant woman
- Not known whether Erlonix is present in human milk
Precautions & Warnings
- Monitore for Interstitial Lung Disease (ILD)
- Monitor renal function and electrolytes
- Monitor periodic liver testing for hepatotoxicity
- Discontinue Erlonix for certain serious adverse reactions
Use in Special Populations
- Pediatric use is not established
- No overall differences in safety or efficacy observed in patients 65 years and older
Overdose Effects
- Higher than recommended doses can lead to severe adverse reactions like diarrhea, rash, and liver transaminase elevation
- Withhold Erlonix in case of suspected overdose and provide symptomatic treatment
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store at a temperature not exceeding 30°C in a dry place, protect from light and moisture